- Home
- GXAI vs KZIA Comparison
GXAI vs KZIA Comparison
Compare GXAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | KZIA |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 100.8M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GXAI | KZIA |
|---|---|---|
| Price | $1.23 | $14.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 3.4M | 206.0K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $271.23 | N/A |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $1.02 | $4.86 |
| 52 Week High | $2.96 | $17.40 |
Technical Indicators
Market Signals| Indicator | GXAI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 64.37 |
| Support Level | $1.06 | $5.62 |
| Resistance Level | $1.32 | $14.57 |
| Average True Range (ATR) | 0.14 | 1.06 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 13.67 | 86.99 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.